1. Progression-free survival improved significantly in patients with low-volume disease who received abiraterone and radiotherapy. 2. The addition of radiotherapy ...
Click here to read this study in the Lancet. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
1. In a retrospective analysis of 59,875 patients with metastatic prostate cancer, varying prognoses were found primarily depending on the ...
1. There was no significant difference in metastasis-free survival between the ADT and non-ADT groups over 10 years. 2. Adverse ...
1. A retrospective analysis demonstrated that prostate-specific antigen (PSA) screening has overall declined in popularity in recent years. 2. Health ...
1. The median progression-free survival was higher in the enzalutamide vs the placebo group (9.5 months vs 8.3 months) 2. ...
1. The median progression-free survival was higher in the enzalutamide vs the placebo group (9.5 months vs 8.3 months). 2. ...
1. A combination of androgen deprivation therapy, docetaxel, and abiraterone (“triplet therapy”) had the best overall survival and progression-free survival ...
1. Overall survival was significantly longer in patients taking darolutamide in tandem with androgen-deprivation therapy and docetaxel. 2. Frequency of ...
1. Ipatasertib-abiraterone treatment significantly improved progression-free survival compared to placebo-abiraterone in patients with PTEN-loss metastatic castration-resistant prostate cancer. 2. Grade 3 ...
